Despite the wide availability of treatments for autoimmune, inflammatory and allergic diseases, the response to therapy and the disease progression is unpredictable and varies from patient to patient.
In addition, by using existing data and samples from other existing clinical trials and studies, the consortium will identify solid biomarker signatures as well as molecular pathways and mechanisms linked to response and non-response to therapy.
This new project is funded by the Innovative Medicine Initiative, a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA) which provides funding for health research and innovation. EFA is one of the project partners with the specific role of involving patients and helping researchers and clinicians understand and gain insights from their experience.
The project will kick-off in September 2019. We will share material and online resources as soon as available.